{"id":618382,"date":"2022-09-26T18:42:02","date_gmt":"2022-09-26T18:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=618382"},"modified":"2022-09-26T18:42:02","modified_gmt":"2022-09-26T18:42:02","slug":"severe-asthma-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-2032-estimates-delveinsight-astrazeneca-tezspiretezepelumab-gsk3511294-depemokimab-novartis-sanofi","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/severe-asthma-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-2032-estimates-delveinsight-astrazeneca-tezspiretezepelumab-gsk3511294-depemokimab-novartis-sanofi_618382.html","title":{"rendered":"Severe Asthma Market to Grow at a Substantial Growth Rate During the Forecast Period (2032) – Estimates DelveInsight | AstraZeneca (Tezspire\/tezepelumab), GSK3511294 (Depemokimab), Novartis, Sanofi"},"content":{"rendered":"
\n
\"Severe<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
As per DelveInsight, the Severe Asthma Market size was found to be USD 6,076 Million in 2021, which is expected to grow by 2032. The market is expected to grow owing to the expected launch of potential therapies, an increase in the diagnosed prevalent population of Severe Asthma, and rising demand for personalized therapies in the 7MM.<\/div>\n

DelveInsight’s “Severe Asthma Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Severe Asthma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Severe Asthma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Severe<\/p>\n

Severe Asthma: An Overview<\/strong><\/p>\n

Asthma is the most common chronic respiratory disease all over the globe. It affects the airways in the lungs, which become inflamed and narrowed due to various triggers, making it harder for air to flow out. A complex activity between airway inflammation and airway remodeling that results in airway hyper-responsiveness (AHR), which further leads to variable and excessive airway contraction.<\/p>\n

There is no single treatment for severe asthma, and the current treatment focuses on controlling the symptoms, managing airway inflammation, and preventing lung damage. Besides inhalers, severe asthmatics are prescribed inhaled corticosteroids and additional long-term controller medicines like bronchodilators, leukotriene receptor antagonists, LAMAs, LABAs, and slow-release theophylline. <\/em><\/p>\n

Severe Asthma Market Key Facts<\/strong><\/p>\n